Chemical industry – Page 65
-
Business
DuPont found liable for cancer case
US court orders firm to pay $1.6m in damages for disease linked to contaminated water supply
-
Business
Monsanto plans 2600 layoffs
Sales losses prompt agrochemical giant to slash workforce by 12% over the next two years
-
Business
EPA fines Mosaic Fertilizer over hazardous waste handling
US Environmental Protection Agency agrees settlement contract including $8m penalty and $800m in investments
-
Business
Controversial new trade deal finalised
The Trans-Pacific Partnership could raise the price of medicines, especially in developing nations
-
Business
Bristol-Myers Squibb fined for alleged Chinese bribes
US Securities and Exchange Commission accepts $14m settlement for charges covering the last five years
-
Business
Safety board fills in details of deadly DuPont leak
In interim investigation has outlined the events and safety failings leading to a methyl mercaptan release that killed four workers
-
Opinion
Human capital
Business leader: Incubators and hubs for small and medium-sized enterprises are all the fashion
-
Opinion
What the market will bear?
Martin Shkreli’s monopolising model poses some uncomfortable questions for the pharma industry, says Derek Lowe
-
Business
Drax pulls out of carbon capture power station plans
Energy giant says government policies have slashed income and made carbon capture project too costly
-
Opinion
Spice up your compounds
An occasional foray into uncharted territory is the hot sauce of medicinal chemistry, says Derek Lowe
-
Business
Bayer CropScience pays $5.6m to settle 2008 accident charges
Fine will fund environmental projects, fire department upgrades and wastewater treatment facilities
-
Business
Cosmetics deals push skin 3D bioprinting
Interest for testing from L’Oréal, BASF and Procter & Gamble could be a stepping stone towards bespoke organs
-
Business
Amgen expands cardiovascular portfolio with Dezima acquisition
Amgen’s $300 million purchase of Dutch biotech gives the company the potential to offer more varied treatment options to lower cholesterol
-
Business
Merger fever sweeps pharma
The life sciences sector has been gripped by a mergers and acquisition frenzy, and it looks set to continue. But what does it mean for the industry?
-
Business
Syngenta to sell off seed business after failed Monsanto takeover
Syngenta to restore shareholder confidence following a series of failed takeover bids by Monsanto
-
Business
Cancer Drugs Fund axes 23 treatments
The UK government has cut down the list of cancer therapies it will pay for through the Cancer Drugs Fund
-
Business
US regulator reprimands Cepheid for norovirus diagnosis tool quality
Diagnostics firm has 15 days to respond to violations laid out by regulator
-
Business
Novartis to buy experimental MS drug from GSK in $1bn deal
Deal will help to bolster Novartis’s pipeline for neurological disorder treatments
-
Business
FDA takes action to remove biosimilars roadblock
The US Food and Drug Administration proposes system to name biosimilar drugs
-
Opinion
A risky business
Graduate research is likely the most risky time of a chemist’s career, says Derek Lowe